Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ARGX, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA | Options-implied move |
|---|---|---|---|---|---|
| 2027-02-18 | efgartigimod | pediatric generalized myasthenia gravis | sBLA | 88% | ±17% by Feb 19 |
Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Nov 17). It prices every move until that expiry, not only the FDA decision.
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Efgartigimod Alfa FDA approved Dec 2021 · Vyvgart |
Myasthaenia Gravis | Phase 3 · NCT06765161 | Recruiting |
| EFG PH20 SC | Active Idiopathic Inflammatory Myopathy | Phase 2/3 · NCT05523167 | Completed |
| Empasiprubart | Multifocal Motor Neuropathy (MMN) | Phase 3 · NCT06742190 | Active not recruiting |
| Empasiprubart IV | Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 · NCT07091630 | Recruiting |
| Efgartigimod PH20 (ARGX-113) SC | Primary Sjogrens Disease | Phase 3 · NCT06684847 | Active not recruiting |
| Efgartigimod IV or Efgartigimod PH20 SC | Generalized Myasthenia Gravis | Phase 2/3 · NCT05374590 | Enrolling by invitation |
| Efgartigimod IV | Primary Immune Thrombocytopenia (ITP) | Phase 3 · NCT06544499 | Recruiting |
| IVIg | Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 · NCT06920004 | Recruiting |
| Adimanebart IV | Congenital Myasthenic Syndrome | Phase 3 · NCT07746089 | Not yet recruiting |
| ARGX-121 | Immunoglobulin A Nephropathy (IgAN) | Phase 2 · NCT07773727 | Recruiting |
| Immunoglobulin | Guillain-Barré Syndrome (GBS) | Phase 2 · NCT07821762 | Not yet recruiting |
| Cusatuzumab | Leukemia, Myeloid, Acute | Phase 2 · NCT04023526 | Active not recruiting |
| Anti-MuSK Agonistic Monoclonal Antibody ARGX-119 | Spinal Muscular Atrophy (SMA) | Phase 2 · NCT07287982 | Recruiting |
| ARGX-117 | Delayed Graft Function | Phase 2 · NCT05907096 | Active not recruiting |
| empasiprubart SC AI | Healthy Volunteers | Phase 1 · NCT07612020 | Recruiting |
| Efgartigimod PH20 SC via PFS | Healthy Volunteer | Phase 1 · NCT07782775 | Completed |
Also used in these trials (approved or third-party drugs, not ARGX's own candidates): Azacitidine, Venetoclax.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ARGX holds $5.2B in cash and short-term investments and its operations are currently cash-flow neutral or positive.
Dilution pressure: 8 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ARGX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR LLC | Institution (13G, 5%+) | 6,178,792 | 9.98% | 2026-09-30 |
| Janus Henderson Group Ltd. | Institution (13F) | 2,391,136 | 3.86% | 2026-09-30 |
| Capital World Investors | Institution (13F) | 2,279,203 | 3.68% | 2026-09-30 |
| Price (T.Rowe) Associates Inc | Institution (13F) | 2,239,720 | 3.62% | 2026-09-30 |
| Artisan Partners Limited Partnership | Institution (13F) | 1,165,747 | 1.88% | 2026-09-30 |
| Avoro Capital Advisors LLC | Institution (13F) | 1,000,000 | 1.62% | 2026-09-30 |
| Blackrock Inc. | Institution (13F) | 879,255 | 1.42% | 2026-09-30 |
| Wellington Management Group, LLP | Institution (13F) | 715,939 | 1.16% | 2026-09-30 |
| RTW Investments LP | Institution (13F) | 711,584 | 1.15% | 2026-09-30 |
| Morgan Stanley | Institution (13F) | 586,527 | 0.95% | 2026-09-30 |
Share count 61,883,306 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ARGX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →